Abstracts tagged "platelets and thrombosis"

Abstract Number: 223 • 2015 ACR/ARHP Annual Meeting
Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events
Richard Conway¹, Claire-Louise Murphy², Anne Madigan², Patricia Kavanagh², Liz Geraghty², Laura Helbert², Kelly Stephens³, John J. Carey⁴, Eimear Dunne⁵, Dermot Kenny⁵ and Geraldine M. McCarthy⁶, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 2, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Mater Misericordiae University Hospital, Clinical Research Center, Dublin, Ireland, ⁴Rheumatology, Galway University Hospitals, Galway, Ireland, ⁵Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁶University College Dublin, Dublin, Ireland
Background/Purpose: Patients with inflammatory arthritis, including gout, have an increased risk of cardiovascular events and mortality. Increased platelet reactivity is a risk marker for cardiovascular…
Abstract Number: 3085 • 2015 ACR/ARHP Annual Meeting
Platelet Activation and Endothelial Reactivity in the Pathogenesis of Tissue Inflammation/Injury in Systemic Lupus Erythematosus
Robert Clancy¹, Sokha Nhek², Jonathan Newman³, Janet Nwaukoni¹, Sara Rasmussen⁴, Jill P. Buyon¹, Maya Rubin⁵, Kristen Lee¹ and Jeffrey Berger⁵, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Medicine, Division of Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for widespread endothelial dysfunction, vascular thromboses, and premature cardiovascular disease. Enhanced platelet activation and…
Abstract Number: 1980 • 2014 ACR/ARHP Annual Meeting
Thrombospondin-1 Is Elevetad in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Soluble Fas Ligand and Free Active TGF-B levels
Markos Patsouras¹, Marina Sikara², Athanasios G. Tzioufas² and Panayiotis Vlachoyiannopoulos², ¹PATHOPHYSIOLOGY DEPARTMENT, UNIVERSITY OF ATHENS, School of Medicine, National University of Athens, Athens, Greece, ²Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose Antiphospholipid syndrome (APS) is an acquired thombophillia characterized by recurrent thromboembolism and pregnancy morbidity. Thrombospondin (TSP-1) is a matricellular glycoprotein with antiangiogenic and proapoptotic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].